Proteomics as a tool for understanding schizophrenia

Clinical Psychopharmacology and Neuroscience

Volumn 9, Issue 3, 2011, Pages 95-101

  Martins de Souza, Daniel ^a,b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Calcium; Energy metabolism; Myelin; Oligodendrocytes; Proteomics; Schizophrenia

Indexed keywords

AUTOPSY; BIOCHEMISTRY; BRAIN TISSUE; CALCIUM HOMEOSTASIS; CELL METABOLISM; CLINICAL ASSESSMENT TOOL; CYTOSKELETON; DRUG TARGETING; ENERGY METABOLISM; HUMAN; METABOLOMICS; OLIGODENDROGLIA; PROTEOMICS; REVIEW; SCHIZOPHRENIA; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 84855427185     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2011.9.3.95     Document Type: Review

References (66)

1. Freedman R. Schizophrenia. N Engl J Med 2003;349:1738-1749.
2. Gejman PV, Sanders AR, Duan J. The role of genetics in the etiology of schizophrenia. Psychiatr Clin North Am 2010;33:35-66.
3. Barch DM. The cognitive neuroscience of schizophrenia. Annu Rev Clin Psychol 2005;1:321-353.
4. Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 2001;24:167-202.
5. Steriade M, Llinás RR. The functional states of the thalamus and the associated neuronal interplay. Physiol Rev 1988;68: 649-742.
6. Andreasen NC, Arndt S, Swayze V 2nd, Cizadlo T, Flaum M, O'Leary D, et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 1994;266:294-298.
7. Luu P, Posner MI. Anterior cingulate cortex regulation of sympathetic activity. Brain 2003;126:2119-2120.
8. Benes FM. Neurobiological investigations in cingulate cortex of schizophrenic brain. Schizophr Bull 1993;19:537-549.
9. Carter CS, MacDonald AW 3rd, Ross LL, Stenger VA. Anterior cingulate cortex activity and impaired self-monitoring of performance in patients with schizophrenia: an event-related fMRI study. Am J Psychiatry 2001;158:1423-1428.
10. Benes FM, Bird ED. An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients. Arch Gen Psychiatry 1987;44:608-616.
11. Deakin JF, Simpson MD. A two-process theory of schizophrenia: evidence from studies in post-mortem brain. J Psychiatr Res 1997;31:277-295.
12. Bogerts B. Recent advances in the neuropathology of schizophrenia. Schizophr Bull 1993;19:431-445.
13. Marini A, Spoletini I, Rubino IA, Ciuffa M, Bria P, Martinotti G, et al. The language of schizophrenia: an analysis of micro and macrolinguistic abilities and their neuropsychological correlates. Schizophr Res 2008;105:144-155.
14. Antonova E, Kumari V, Morris R, Halari R, Anilkumar A, Mehrotra R, et al. The relationship of structural alterations to cognitive deficits in schizophrenia: a voxel-based morphometry study. Biol Psychiatry 2005;58:457-467.
15. Martí-Bonmatí L, Lull JJ, García-Martí G, Aguilar EJ, Moratal-Pérez D, Poyatos C, et al. Chronic auditory hallucinations in schizophrenic patients: MR analysis of the coincidence between functional and morphologic abnormalities. Radiology 2007;244:549-556.
16. Wilkins MR, Pasquali C, Appel RD, Ou K, Golaz O, Sanchez JC, et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (NY) 1996;14:61-65.
17. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250:4007-4021.
18. Martins-De-Souza D, Dias-Neto E, Schmitt A, Falkai P, Gormanns P, Maccarrone G, et al. Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry 2010;11: 110-120.
19. Gygi SP, Corthals GL, Zhang Y, Rochon Y, Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A 2000;97:9390-9395.
20. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999;17:676-682.
21. Domon B, Aebersold R. Options and considerations when selecting a quantitative proteomics strategy. Nat Biotechnol 2010;28:710-721.
22. Maccarrone G, Turck CW, Martins-de-Souza D. Shotgun mass spectrometry workflow combining IEF and LC-MALDITOF/ TOF. Protein J 2010;29:99-102.
23. Michalski A, Cox J, Mann M. More than 100,000 detectable peptide species elute in single shotgun proteomics runs but the majority is inaccessible to data-dependent LC-MS/MS. J Proteome Res 2011;10:1785-1793.
24. Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S, et al. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res 2010;44:1176-1189.
25. McLoughlin GA, Ma D, Tsang TM, Jones DN, Cilia J, Hill MD, et al. Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J Proteome Res 2009;8:1943-1952.
26. Ditzen C, Varadarajulu J, Czibere L, Gonik M, Targosz BS, Hambsch B, et al. Proteomic-based genotyping in a mouse model of trait anxiety exposes disease-relevant pathways. Mol Psychiatry 2010;15:702-711.
27. Martins-de-Souza D, Schmitt A, Röder R, Lebar M, Schneider-Axmann T, Falkai P, et al. Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. J Psychiatr Res 2010;44:989-991.
28. Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Gulyás E, Eberlin MN, et al. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res 2009;43: 978-986.
29. Martins-de-Souza D, Gattaz WF, Schmitt A, Novello JC, Marangoni S, Turck CW, et al. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 2009;9:17.
30. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E, et al. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2009;259:151-163.
31. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC, et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 2009;116:275-289.
32. Kooy FH. Hyperglycemia in mental disorders. Brain 1919; 42:214-289.
33. Martins-de-Souza D, Harris LW, Guest PC, Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal 2011;15:2067-2079.
34. Wolkin A, Jaeger J, Brodie JD, Wolf AP, Fowler J, Rotrosen J, et al. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry 1985;142:564-571.
35. Fucetola R, Newcomer JW, Craft S, Melson AK. Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia. Psychiatry Res 1999;88:1-13.
36. Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A, et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients. Mol Psychiatry 2010;15:118-119.
37. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000;28:27-30.
38. Bergson C, Levenson R, Goldman-Rakic PS, Lidow MS. Dopamine receptor-interacting proteins: the Ca(2+) connection in dopamine signaling. Trends Pharmacol Sci 2003; 24:486-492.
39. Greengard P. The neurobiology of slow synaptic transmission. Science 2001;294:1024-1030.
40. Zeng H, Chattarji S, Barbarosie M, Rondi-Reig L, Philpot BD, Miyakawa T, et al. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 2001;107:617-629.
41. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-152.
42. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001;41:237-260.
43. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature 1999;399(6738 Suppl):A7-A14.
44. Fu Y, Wang H, Huff TB, Shi R, Cheng JX. Coherent anti-Stokes Raman scattering imaging of myelin degradation reveals a calcium-dependent pathway in lyso-PtdCho-induced demyelination. J Neurosci Res 2007;85:2870-2881.
45. Du Y, Dreyfus CF. Oligodendrocytes as providers of growth factors. J Neurosci Res 2002;68:647-654.
46. Deng W, Poretz RD. Oligodendroglia in developmental neurotoxicity. Neurotoxicology 2003;24:161-178.
47. Kubicki M, Park H, Westin CF, Nestor PG, Mulkern RV, Maier SE, et al. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage 2005;26:1109-1118.
48. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, et al. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry 2004; 56:41-45.
49. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003;60:443-456.
50. Honer WG, Falkai P, Chen C, Arango V, Mann JJ, Dwork AJ. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience 1999; 91:1247-1255.
51. Martins de Souza D, Dias-Neto E. RNA Biomarkers in Schizophrenia. In: Turck CW, editor. Biomarkers for Psychiatric Disorders, Vol. 1. Munich: Springer; 2009. p.97- 127.
52. Martins-de-Souza D. Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. J Psychiatr Res 2010;44:149-156.
53. Bifulco M, Laezza C, Stingo S, Wolff J. 2′,3′-Cyclic nucleotide 3′-phosphodiesterase: a membrane-bound, microtubule-associated protein and membrane anchor for tubulin. Proc Natl Acad Sci U S A 2002;99:1807-1812.
54. Boccaccio GL, Colman DR. Myelin basic protein mRNA localization and polypeptide targeting. J Neurosci Res 1995;42:277-286.
55. Sprinkle TJ, Lanclos KD, Lapp DF. Assignment of the human 2′,3′-cyclic nucleotide 3′-phosphohydrolase gene to chromosome 17. Genomics 1992;13:877-880.
56. Peirce TR, Bray NJ, Williams NM, Norton N, Moskvina V, Preece A, et al. Convergent evidence for 2′,3′-cyclic nucleotide 3′- phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch Gen Psychiatry 2006;63:18-24.
57. Connor JR. Iron acquisition and expression of iron regulatory proteins in the developing brain: manipulation by ethanol exposure, iron deprivation and cellular dysfunction. Dev Neurosci 1994;16:233-247.
58. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 1999;46:729-739.
59. Wojda U, Salinska E, Kuznicki J. Calcium ions in neuronal degeneration. IUBMB Life 2008;60:575-590.
60. Martins-de-Souza D. Is the word 'biomarker' being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci 2010;260:561-562.
61. Benitez-King G, Ramírez-Rodríguez G, Ortíz L, Meza I. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 2004;3:515-533.
62. Bernstein HG, Steiner J, Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother 2009;9:1059-1071.
63. Steffek AE, McCullumsmith RE, Haroutunian V, Meador- Woodruff JH. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res 2008;103:71-82.
64. Sweitzer SM, Hinshaw JE. Dynamin undergoes a GTP-dependent conformational change causing vesiculation. Cell 1998;93:1021-1029.
65. Dale LB, Babwah AV, Ferguson SS. Mechanisms of metabotropic glutamate receptor desensitization: role in the patterning of effector enzyme activation. Neurochem Int 2002;41:319-326.
66. Ben-Shachar D. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. J Neural Transm 2009;116:1383-1396.